In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

AstraZeneca PLC closed 23.68% short of its 52-week high of £133.88, which the company achieved on September 3rd.

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

Dubai Science Park is part of TECOM Group's portfolio of business districts, which include Dubai Internet City, Dubai Media ...

Since ADBA published its report on the role of green gases in December last year, the first unsubsidised biomethane plant has ...

Imagine a world without disease. Sounds utopian? AI just made it a multibillion-dollar bet to discover drugs – and forget Big ...

FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in ...

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

Jazz Pharmaceuticals plc is a Buy with its robust portfolio, potential FDA approvals, and innovative oncology treatments.

Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.